This site has circled the subject of bone twice without landing on it. The page on GLP-1s in later life, GLP-1s After 65: What Changes, reports a fracture imbalance in one trial's oldest subgroup, and the page on resistance training, Two Days of Strength Training: The GLP-1 Muscle Insurance, covers muscle in detail. Bone itself has gone unmentioned, which is a gap, because it is a fair thing to wonder about when weight comes off quickly. The honest version of this page is largely about how little is settled.
What the Wegovy label says
Only one label in the class reports fracture data at all, and it is Wegovy's. Its adverse reactions section carries a dedicated Fractures entry with two findings. In the cardiovascular outcomes trial in adults, more fractures of the hip and pelvis were reported on Wegovy than on placebo in female patients, 1 percent (24 of 2,448) versus 0.2 percent (5 of 2,424), and in patients ages 75 years and older, 2.4 percent (17 of 703) versus 0.6 percent (4 of 663).
The second finding is closer than the first. In a clinical trial in adults with MASH, fractures occurred in 4.4 percent of Wegovy-treated patients, 2.6 cases per 100 patient years, compared with 3.3 percent of placebo-treated patients, 2 cases per 100 patient years. Fractures were reported in both males and females, with a median age of 61 years and a range of 44 to 75. The Geriatric Use section of the label repeats the 75-and-older finding and adds that patients in that age group, in both arms, reported more serious adverse reactions overall than younger adults did.
Both numbers deserve to be held at once. More fractures were reported on the drug than on placebo in two subgroups of one large trial, and that is what the label says. The absolute numbers are also small, and the MASH comparison, 4.4 against 3.3 percent, is closer than the headline subgroups. Neither reading cancels the other.
What the other labels say
Here the story becomes about silence. The current Ozempic, Zepbound and Mounjaro labels contain no fracture data and no fracture entry at all. And no label in the class mentions bone mineral density or osteoporosis. Those absences need careful reading: a label carries what was studied and submitted for that product, so an empty section is a statement about the trials and the filing, not a demonstrated difference between molecules. Reading the labels as a ranking, with Wegovy as the bone-risk drug and the others as clean, is exactly the mistake the silence invites and exactly the wrong conclusion.
Why one product carries the entry and the others do not comes down to which trials were run, what was measured, and what regulators required each sponsor to report. That is plumbing, not pharmacology. What a reader can take from it is narrower: the only fracture numbers that exist in this class's prescribing information exist in one label, and they are the numbers above.
GLP 1 Tracker AppWeight, protein and activity logged day by day, privately on your phone. The habits that protect muscle and bone start with seeing whether you are keeping them.
Get the app
The open question outside the labels
Beyond the labels there is a research literature on bone density and fracture risk during substantial weight loss, and it genuinely does not agree with itself. Some studies report measurable declines in bone mineral density alongside large weight loss. Some meta-analyses in people with type 2 diabetes have not found a significant increase in fracture risk. Some cohort work points in each direction. We name no percentages and no specific studies here, because the site's standard is primary sources, and a literature in disagreement cannot be summarized in a number without inventing a certainty nobody has.
The honest summary is that this is an open question, actively being worked out, and an article that resolved it for you would be making things up. What can be stated with confidence is the label data above. The confident-sounding secondary material that circulates, conference abstracts and clinic blog posts, does not meet the bar this site holds itself to, and we prefer saying nothing to repeating that material.
What is not in dispute
One finding sits underneath all of it and predates these medicines entirely: losing a lot of weight, by any means, is associated with loss of bone as well as fat and muscle. That is long established in weight-loss research generally and is not specific to GLP-1s. It is one of the reasons substantial weight loss is treated as a physiological event worth supporting rather than merely a goal worth reaching, and it is why the muscle-preserving habits get recommended so consistently.
Those habits are the levers people are usually pointed at, and they are the same ones this site already covers. Adequate protein, with the commonly cited GLP-1 guidance of roughly 1.0 to 1.5 g per kg of body weight daily, detailed at Protein Goals on GLP-1s: Protecting Muscle While Losing Weight. And resistance training, covered at Two Days of Strength Training: The GLP-1 Muscle Insurance, which loads bone as well as muscle; bone responds to loading the way muscle does, which is why the same exercise defends both.
What links the levers is that they are modest, available and unglamorous, which is usually the sign of advice that survives being checked. None of them is specific to fracture risk, none of them requires acting on the open question above, and all of them are worth doing for reasons this site has already argued on their own pages. Bone health simply adds one more line to the case for the same habits rather than demanding a new regimen, and a question about how they apply to you is an ordinary one to bring to a clinician or dietitian.
Calcium, vitamin D, and age
Calcium and vitamin D come up constantly in this conversation, and that is a fair report of where the discussion lives. What this article will not do is give doses, amounts, or a recommendation to supplement: this site's stance on supplements is that they are a clinician question, laid out at Supplements on a GLP-1: What to Ask Your Clinician About, and it applies in full here. A dietitian or clinician can weigh diet, sun exposure, lab work and history; an article cannot.
Age changes the picture, and the label itself says so. The 75-and-older subgroup is where the fracture imbalance was largest and where more serious adverse reactions appeared overall, in both arms, which is why the prescriber conversation matters most for older adults and why GLP-1s After 65: What Changes is the companion page to this one. Whether any scan, test or supplement makes sense for a particular person at a particular age is precisely the judgment this article exists to route to a clinician rather than replace.
That is the whole honest position. One label reports fracture numbers, small in absolute terms and concentrated in two subgroups of one trial; the other labels are silent; no label addresses bone density; the wider literature is unresolved; and the practical habits that defend bone are the ones already recommended for defending everything else. If a question in this neighborhood is yours, it belongs with the prescriber, who has both the label and your history in front of them.
Frequently asked questions
Do GLP-1 medicines cause fractures?
Only one label in the class reports fracture data at all, and it belongs to Wegovy. In its cardiovascular outcomes trial, more fractures of the hip and pelvis were reported on Wegovy than on placebo in female patients, 1 percent versus 0.2 percent, and in patients ages 75 and older, 2.4 percent versus 0.6 percent. In a trial in adults with MASH, fractures occurred in 4.4 percent of Wegovy-treated patients against 3.3 percent on placebo. That is what the label says; it is not a statement about anybody's individual bones.
Does Ozempic or Mounjaro cause bone loss?
The current Ozempic, Zepbound and Mounjaro labels contain no fracture data and no fracture entry at all, and no label in the class mentions bone mineral density or osteoporosis. An absence on a label reflects what was studied and submitted for that product, not a difference between molecules, so the labels cannot be read as a ranking. Whether these medicines affect bone over long periods is an open research question, and this article will not resolve it.
Is bone density loss a side effect of rapid weight loss?
Losing a lot of weight, by any means, is associated with loss of bone as well as fat and muscle; that association is long established in weight-loss research generally and is not specific to these medicines. Beyond that, the research literature on bone density and fracture risk during substantial weight loss genuinely does not agree with itself, with studies pointing in different directions. The label data are what can be stated with confidence and the rest is actively being worked out.
How can I protect my bones while losing weight on a GLP-1?
The levers usually discussed are the same ones that protect muscle. Protein intake commonly cited for GLP-1 users runs about 1.0 to 1.5 g per kg of body weight daily, and resistance training loads bone as well as muscle, which is why it is the standing recommendation alongside protein. Calcium and vitamin D come up constantly in this conversation and are a dietitian or clinician question; this article gives no doses and makes no supplement recommendation.
Should I get a bone density scan before starting a GLP-1?
Whether any test is warranted is a clinician's call, informed by your age, history and circumstances, and nothing in this article should be read as a suggestion either way. What this article does is report what one label says and name an open question. Age changes the picture, and the 75 and older subgroup in the Wegovy label reported more serious adverse reactions overall, which is one reason the conversation with a prescriber matters most for older adults.